Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:27:10 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Z:NVS - NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) - http://www.novartis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NVS - Z0.291.14·103.250.594.36+1.801.92,338.3217,52617,59193.20  94.495  93.15108.78  92.1916:38:50Apr 1515 min RT 2¢

Recent Trades - Last 10 of 17591
Time ETExPriceChangeVolume
16:38:50Z94.501.931
16:22:59Z94.501.931
16:07:25Z94.30571.7357280
16:00:44Z94.361.799,000
16:00:23Z94.361.79222
16:00:22Z94.361.7937
16:00:21Z94.361.791,239
16:00:21Z94.361.794,594
16:00:21Z94.361.79922
16:00:21Z94.361.792,092

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-15 14:00U:NVSNews ReleaseNew Novartis Fabhalta(TM) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
2024-04-11 07:01U:NVSNews ReleaseArvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC(TM) Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
2024-04-06 16:16U:NVSNews ReleaseNew Novartis data show early addition of twice-yearly* Leqvio(TM) (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
2024-02-14 08:00U:NVSNews ReleaseErasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
2023-12-10 19:39U:NVSNews ReleaseNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta ‚ ® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
2023-12-06 00:18U:NVSNews ReleaseNovartis receives FDA approval for Fabhalta ‚ ® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
2023-09-11 10:00U:NVSNews ReleaseNovartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune ‚ ® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
2023-06-08 07:00U:NVSNews ReleaseKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA